Background: The Consortium for Southeastern Hypertension Control (COSEHC) promotes global risk factor management in patients with metabolic syndrome. The COSEHC Global Vascular Risk Management Study (GVRM) intends to quantify these efforts on long-term patient outcomes. The objectives of this study were to present baseline demographics of patients enrolled in the GVRM, calculate a modified COSEHC risk score using 11 variables (COSEHC-11), and compare it with the original COSEHC-17 and Framingham, Prospective Cardiovascular Münster (PROCAM), and Systemic Coronary Risk Evaluation (SCORE) risk scores.

Methods: Deidentified electronic medical records of enrolled patients were used to calculate the risk scores. The ability of the COSEHC-11 score to predict the COSEHC-17 score was assessed by regression analysis. Raw risk scores were converted to probability estimates of fatal coronary heart disease (CHD) and compared with predicted risks from other algorithms.

Results: Of the 177,404 patients enrolled, 43,676 had data for all 11 variables. The COSEHC-11 score (mean ± standard deviation) of these 43,676 patients was 31.75 ± 11.66, implying a five-year fatal CHD risk of 1.4%. The COSEHC-11 score was highly predictive of the COSEHC-17 score (R² = 0.93; P < 0.0001) and correlated well with the SCORE algorithm.

Conclusion: The COSEHC-11 risk score is statistically similar to the COSEHC-17 risk score and should be a viable tool for evaluating its ability to predict five-year cardiovascular mortality in the coming years.

Keywords: cardiovascular risk, electronic medical records, metabolic syndrome

Introduction

Metabolic syndrome refers to a constellation of cardiovascular risk factors. Although several different definitions of metabolic syndrome exist,1 the US National Cholesterol Education Program Adult Treatment Panel III defines metabolic syndrome as the presence of at least three of five core risk factors: abdominal obesity; insulin resistance, glucose intolerance, or drug treatment for elevated glucose levels; elevated blood pressure or antihypertensive drug treatment; low levels of high-density lipoprotein cholesterol (HDL-C); and elevated triglyceride levels.2 Other factors commonly associated with the metabolic syndrome include vascular inflammation, presence of a prothrombotic state, physical inactivity, aging, and a genetic predisposition.3–5

Improved management of these risk factors is important because the metabolic syndrome strongly predicts the development of cardiovascular disease (CVD). In a large meta-analysis of 172,573 individuals enrolled in longitudinal studies, persons with metabolic syndrome had almost a twofold increased risk of experiencing a cardiovascular event or death compared with those without metabolic syndrome.
(summary risk ratio [RR], 1.78; 95% confidence interval: 1.58, 2.00). The risk remained significant even when adjusting for known cardiovascular risk factors or a history of CVD. Furthermore, there appears to be a gender effect such that women have a greater risk than men (summary RR, 2.63 versus 1.98; \(P = 0.09\)) and a continuum of risk that increases with the number of metabolic syndrome components present.\(^9,10\)

While the American Heart Association and the American College of Cardiology\(^11\) recommend using the Framingham Heart Study global risk assessment scoring system\(^12\) for estimating an individual’s 10-year risk of experiencing a fatal or nonfatal cardiovascular event, this approach has several limitations\(^13\) that are underscored by the more comprehensive global hypertension management guidelines put forth by the European Society of Hypertension and European Society of Cardiology.\(^14\) Although the Framingham scoring system includes the “standard” risk factors of smoking, blood pressure, total cholesterol, HDL-C, blood glucose, sex, and age, exclusion of other recognized risk factors such as left ventricular hypertrophy (LVH) limits its ability to discriminate sensitively between individuals at different levels of cardiovascular risk.\(^15\) Equally important, the generalized application of the Framingham risk score to both sexes and all racial and ethnic groups has been questioned, because the Framingham study was conducted among 5208 predominantly white, healthy individuals living in Framingham, Massachusetts.\(^12,13,16\) For example, in a study that assessed the multiethnic, multiracial applicability of the Framingham risk score, the score was found to be generally predictive for whites and blacks, but systematically overestimated five-year risk in Japanese American and Hispanic men and Native American women.\(^17\) Other studies reported that the Framingham score also overestimates risk in patients from China,\(^17\) The Netherlands,\(^18\) and Ireland and France.\(^19\)

To address these limitations, other risk scoring tools have been developed, including the Prospective Cardiovascular Münster (PROCAM) score, which estimates the 10-year risk of fatal and nonfatal cardiovascular events,\(^20\) and the Systemic Coronary Risk Evaluation (SCORE) score, or Weibull algorithm,\(^21\) which estimates the 10-year risk of fatal cardiovascular events.

In an effort to develop a more accurate and valid risk score for predicting CVD mortality in the southeastern US, a region with a highly diverse population and a historically higher prevalence of CVD and CVD-related mortality,\(^22,23\) the Consortium for Southeastern Hypertension Control (COSEHC) developed an alternative global approach to screening and scoring patients for cardiovascular risk. The COSEHC risk tool includes 17 risk factors and is based on the cardiovascular risk score published by the INDiana Data ANalysis of Antihypertensive intervention trials (INDANA) database study,\(^24\) which included 11 variables.\(^25,26\) The INDANA algorithm calculates the five-year risk of death from CVD. It was derived with data from eight large randomized trials (n = 48,088), all of which assessed antihypertensive drugs versus no intervention and reported mortality by intention to treat. Furthermore, the trials were multinational, which enhanced generalizability, and because follow-up in these trials was stringent, the risk estimators developed were precise.

To validate the discriminative value of the COSEHC risk tool in predicting CVD mortality in the diverse population of the southeastern US, the Global Vascular Risk Management (GVRM) study was initiated. This large-scale prospective study was designed to determine the sensitivity of the COSEHC risk tool. The GVRM also seeks to determine if the COSEHC risk tool can be useful in improving quality of care in the management of vascular disease and the metabolic syndrome by providing benchmarking data on treatment patterns and outcomes to participating COSEHC Cardiovascular Centers of Excellence\(^\text{TM}\) and in assessing the effect of COSEHC-designated treatment goals\(^26\) on patient outcomes at five years.

In this article, the demographic profile and risk factor prevalence of the GVRM study population at baseline are presented, the development of the COSEHC-11 risk score tool is described, and the COSEHC-11 score is compared with the original COSEHC-17 risk score tool, as well as the Framingham, PROCAM, and SCORE (Weibull) risk score algorithms.

**Methods**

**Study design**

The GVRM study is a voluntary, observational, prospective quality improvement initiative conducted at eight COSEHC Cardiovascular Centers of Excellence. The Centers of Excellence network, established in 1998, represents a cooperative initiative of expert health care providers who partner with local health, consumer, employer, and academic groups to develop programs that focus on the treatment, clinical research, and prevention of metabolic syndrome-related CVD. Data were derived from patients who were aged \(\geq 18\) years and met one or more of the following criteria: at least one predefined International Classification of Diseases, 9th Revision (ICD-9) code corresponding to CVD
or risk factors, treatment at a cardiac or vascular-related clinic or department of a participating Center of Excellence, or treatment at a noncardiac-related outpatient clinic associated with a cardiac-related Current Procedural Terminology code. Because this is an observational study, all patients from each participating center are treated per the standard of care for their respective conditions, and no predefined visits, medical or laboratory tests, procedures, or interventions are required.

The 11 variables used in calculating the modified COSEHC-11 risk score are listed in Table 1. Additional variables of interest include those required to calculate the original COSEHC-17 risk score (Table 1). Of the 11 variables necessary to calculate the modified COSEHC score, age, sex, smoking status, and family history of coronary heart disease (CHD) are collected only once; all other data are updated on a quarterly basis from the individual centers and submitted to COSEHC.

**Study duration and outcomes**

A five-year prospective study is planned from a baseline data date of February 4, 2010. The main outcome measures are cardiovascular morbidity and mortality, including the development of CHD, congestive heart failure, stroke, transient ischemic attack, abdominal aortic aneurysm, myocardial infarction, death, renal failure, and diabetic retinopathy.

**Table 1 Variables included in the original COSEHC, modified COSEHC, Framingham, SCORE (Weibull), and PROCAM cardiovascular risk scores**

| Variable                                      | Modified COSEHC | Original COSEHC | Framingham Heart Study | SCORE | PROCAM |
|-----------------------------------------------|-----------------|-----------------|------------------------|-------|--------|
| Age, years                                    |                 |                 |                        |       |        |
| Sex                                           |                 |                 |                        |       |        |
| Total cholesterol, mmol/L                     |                 |                 |                        |       |        |
| HDL-C, mmol/L                                 |                 |                 |                        |       |        |
| LDL-C, mmol/L                                 |                 |                 |                        |       |        |
| Triglycerides, mmol/L                         |                 |                 |                        |       |        |
| Systolic blood pressure, mmHg                 |                 |                 |                        |       |        |
| Smoking status (yes or no)                    |                 |                 |                        |       |        |
| Diabetes mellitus, mmol/L (yes or no)         |                 |                 |                        |       |        |
| Heart history of premature CHD (yes or no)    |                 |                 |                        |       |        |
| ECG-confirmed LVH (yes or no)                 |                 |                 |                        |       |        |
| Height, inches                                |                 |                 |                        |       |        |
| Serum creatinine, μmol/L                      |                 |                 |                        |       |        |
| Homocysteine, μmol/L                          |                 |                 |                        |       |        |
| Prior MI (yes or no)                          |                 |                 |                        |       |        |
| Prior stroke (yes or no)                      |                 |                 |                        |       |        |

Notes: Grey shading indicates the variable is included in the calculation of the risk score. *Diabetes diagnosis based on fasting blood glucose >6.66 mmol/L listed in electronic medical record. **For COSEHC score, required only for males aged <60 years.

Abbreviations: CHD, coronary heart disease; COSEHC, Consortium for Southeastern Hypertension Control; ECG, electrocardiogram; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; LVH, left ventricular hypertrophy; MI, myocardial infarction; PROCAM, Prospective Cardiovascular Münster; SCORE, Systemic Coronary Risk Evaluation.
since birth. The data will never be “reidentified,” and ICON will never have access to actual calendar dates.

Statistical methods
The COSEHC-11 risk score is an additive score calculated using separate algorithms for men and women. The individual scoring elements are for age (five-year ranges), smoking status (with differential scores for each age range), systolic blood pressure ranges, laboratory test score ranges, and patient history variables. The final COSEHC-11 score is the sum of each of these individual scoring elements. The primary baseline analysis for this article involved the calculation of the COSEHC-11 risk score and included only those patients with all 11 required data elements. An exception for this requirement was made for women and men aged > 59 years with missing data for family history of myocardial infarction. This exception is made because the COSEHC risk score only uses premature family CHD for male patients aged < 60 years. For the current report, the following applies: if a patient had multiple visits during the six months prior to the end of the baseline period (February 4, 2010), data from the last visit were used; if laboratory values or blood pressure readings were missing from the last visit, data from the most recent prior visit were used, with a maximum carry-forward time of 12 months; and patient history variables (ie, smoking and diabetes status, family CHD history, and LVH) had unlimited carry-forward times.

The impact of using < 11 variables to estimate the modified COSEHC-11 risk score was gauged by including patients with incomplete data. Only patients with ≥ 8 of 11 variables were considered for this analysis. Three methods of data imputation were used to improve the accuracy of the modified COSEHC risk score. The first imputation method increased the amount of data that laboratory and blood pressure values were carried forward to replace missing values; thus, instead of the original cutoff time of 12 months, unlimited carry-forward was used. The second imputation augmented the results of the first imputation with pharmacy data. When patients were missing data for diabetes status, we checked for the presence of diabetes-specific medications (ie, insulin detemir, insulin glargine, human recombinant insulin, insulin lispro, metformin, pioglitazone, and rosiglitazone). Patients with at least one of these medications had their diabetes status changed from “missing” to “diabetic.” Lastly, multiple imputations were implemented using SAS® PROC MI (SAS Institute, Inc., Cary, NC) with the Markov chain Monte Carlo (MCMC) method. The MCMC method can be used when some of the missing variables (eg, laboratory tests) have arbitrarily missing patterns.27 MCMC simulation constructs a Markov chain that is long enough for the distribution of the elements to stabilize to a stationary distribution (the distribution of interest). Through repeated simulations of the steps of this chain, the method simulates draws from the distribution of interest.27 This allows for simulations from a wide range of distributions without being computationally burdensome.28 For the COSEHC dataset, a set of mean and covariance priors were created using data from site 4 (n = 1319), which had complete data on all patients and good laboratory test compliance. These priors were used by the MCMC algorithm to improve its imputation.

To validate the modified COSEHC score, a regression analysis was used to estimate the full COSEHC-17 score using the modified COSEHC-11 score as a predictor. To perform this analysis, the original COSEHC-17 risk score was calculated for the subgroup of patients with complete data for all COSEHC-17 variables. The modified COSEHC-11 risk score was also calculated for this subgroup. The modified COSEHC-11 risk score was used as the only predictor for the full COSEHC-17 risk score using linear regression. This analysis was performed to demonstrate that the COSEHC-11 risk score could serve as a proxy for the full COSEHC-17 risk score. In addition, we used the results from this regression analysis to transform the modified COSEHC-11 risk score into an estimated CHD event probability and to characterize the distribution of CHD event risk within the study population.

To compare the modified COSEHC risk score and its resulting event probability with other risk indices, the subset of patients who had complete data for all 11 variables to calculate Framingham, PROCAM, and SCORE (Weibull) risk scores was used. These risk scores were calculated using both the nonimputed and multiple imputation datasets. It should be noted that the SCORE (Weibull) risk score predicts the 10-year risk of fatal CHD events, whereas the Framingham and PROCAM risk indices predict both fatal and nonfatal events over 10 years. Table 1 lists the required data elements for each risk score. All data are reported as mean ± 1 standard deviation (SD) of the mean.

Results
Baseline demographics
A total of 177,404 patients from eight participating COSEHC centers were found to be eligible for inclusion in the GVRM study and represent the baseline population. Of these patients, 70,567 had at least 8 out of 11 required COSEHC variables present in their electronic medical record, including 43,676
who had complete data for all 11 variables. Table 2 presents the characteristics of the 70,567 patients with eight or more data elements complete. Of these 70,567 patients, the mean age was 60 years and 54% were women. Diabetes mellitus was present in 35% of the 65,391 patients for whom the status was available. The most commonly missing data elements among this group were for ethnicity, family CHD history, and clinical diagnosis of LVH. Of the 18,725 patients whose race or ethnicity was known, 70% were white, 20% were black, 1% were Hispanic, and 8% were classified as other.

**COSEHC-11 scores**

COSEHC-11 scores were calculated for the 43,676 patients with complete baseline data for all 11 variables. As can be seen in Table 3, data completeness varied across the centers, with the proportion of patients for whom complete baseline data were available for all 11 variables ranging from 0.3% (center 7) to 63.4% (center 3). Among the 43,676 patients with complete data, the mean COSEHC-11 score was 31.75 ± 11.66. The range across the centers was 30.93 to 36.85. One interesting finding is the relative stability of the SD across sites and between the individual sites and the total cohort (Table 3).

Table 3 also displays the COSEHC-11 scores that result from the three methods of data imputation. The first method of imputation, with no limit on carry-forward time, resulted in the availability of 43,861 patients for analysis, an increase of 185 patients over no imputation. The relatively small number of additional patients is consistent with the availability of complete laboratory and blood pressure records for most patients (Table 2). The second method of imputation (pharmacy imputation of diabetes medications), which could only add patients with diabetes, added no additional patients. While there were 5176 patients with a missing diabetes history, patients with no diabetes records were typically missing other patient history variables in addition to their diabetes status. Thus, the imputation using pharmacy records did not produce any new complete records, although it did find 79 patients from this group with a positive history of diabetes-specific medications.

The MCMC method of imputation increased the sample size from 43,676 to 70,567. The average COSEHC-11 score in the imputed group decreased slightly from 31.75 ± 11.66 to 31.24 ± 11.24 (Table 3). Center 7, which had the fewest number of patients with available data for all 11 variables, showed the largest change in risk score upon imputation, decreasing from 36.85 ± 11.13 to 32.12 ± 10.94. Of the five sites having ≥1000 patients with complete data for all 11 variables, multiple imputation changed the average COSEHC-11 score by <one point.

**Comparison of COSEHC-11 and COSEHC-17 scores**

Figure 1 shows the results of a linear regression model of the more comprehensive COSEHC-17 score using the COSEHC-11 score as the predictor. This regression was performed on the subset of 735 patients who had available data for all 17 COSEHC variables except homocysteine. (Homocysteine levels were available for only one patient in this cohort and were therefore excluded as a required variable.) The COSEHC-11 coefficient was a statistically significant predictor of the COSEHC-17 score ($P < 0.0001; R^2 = 0.93$). This suggests that the COSEHC-11 risk score is highly correlated with the full COSEHC-17 risk score, and that a simple linear transformation of the COSEHC-11 score can yield a good approximation of the full COSEHC-17 risk score, and therefore, cardiovascular event probability.

---

**Table 2** Baseline demographics of the 70,567 patients with ≥eight COSEHC-11 variables

| Variables                        | Descriptive statistic | N* |
|----------------------------------|-----------------------|----|
| Age, years                       | 60 ± 14               | 70,567 |
| Women, n (%)                     | 38,238 (54%)          | 70,567 |
| Race/ethnicity                   |                       |     |
| White, n (%)                     | 13,159 (70%)          | 18,725 |
| Black, n (%)                     | 3755 (20%)            | 18,725 |
| Hispanic, n (%)                  | 105 (1%)              | 18,725 |
| Other, n (%)                     | 1560 (8%)             | 18,725 |
| Clinical history                 |                       |     |
| Current smoker, n (%)            | 14,793 (27%)          | 55,002 |
| Diabetes mellitus, n (%)         | 22,895 (35%)          | 65,391 |
| Premature CHD in family, n (%)   | 9920 (40%)            | 25,070 |
| Left ventricular hypertrophy, n (%)| 6284 (12%)        | 52,334 |
| Clinical and laboratory valuesa |                       |     |
| Systolic blood pressure, mmHg    | 129 ± 17              | 70,036 |
| Diastolic blood pressure, mmHg   | 77 ± 11               | 70,032 |
| Total cholesterol, mmol/Lc       | 4.8 ± 1.1             | 69,949 |
| HDL-C, mmol/Lc                   | 1.2 ± 0.3             | 69,363 |
| LDL-C, mmol/Lc                   | 2.8 ± 0.9             | 69,474 |
| Triglycerides, mmol/Lc           | 1.7 ± 1.0             | 70,384 |

Notes: Age and clinical and laboratory values are presented as mean ± standard deviation. *The total number of patients available for each variable is <70,567, reflecting missing data for the various elements. The exception is age and sex, which were required for all patients; *All values are from the last recorded assessment. If the last assessment occurred >12 months before the last visit, the results were not used; *To convert total, HDL-C and LDL-C levels from mmol/L to mg/dL, multiply by 38.61; *To convert triglycerides from mmol/L to mg/dL, multiply by 88.50.

Abbreviations: CHD, coronary heart disease; COSEHC, Consortium of Southeastern Hypertension Control; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol.
Table 3 Average COSEHC-11 score by site calculated with and without imputation

|                     | Site 1 | Site 2 | Site 3 | Site 4 | Site 5 | Site 6 | Site 7 | Site 8 | Total  |
|---------------------|--------|--------|--------|--------|--------|--------|--------|--------|--------|
| **Total population** | 2822   | 62,222 | 31,946 | 1319   | 4865   | 34,867 | 4930   | 34,433 | 177,404|
| **No imputation**   |        |        |        |        |        |        |        |        |        |
| Total available     | 1420   | 11,420 | 20,239 | 737    | 939    | 6047   | 13     | 2861   | 43,676 |
| for analysis        |        |        |        |        |        |        |        |        |        |
| COSEHC score        | 31.94  | 31.95  | 30.93  | 31.07  | 35.90  | 31.18  | 36.85  | 36.60  | 31.75  |
| (9.08)              | (10.76)| (12.65)| (9.53) | (9.97) | (11.08)| (11.13)| (9.46) | (11.66)|        |
| **Unlimited carry-forward** |        |        |        |        |        |        |        |        |        |
| Total available     | 1420   | 11,420 | 20,239 | 737    | 1124   | 6047   | 13     | 2861   | 43,861 |
| for analysis        |        |        |        |        |        |        |        |        |        |
| COSEHC score        | 31.94  | 31.95  | 30.93  | 31.07  | 36.13  | 31.18  | 36.85  | 36.60  | 31.77  |
| (9.08)              | (10.76)| (12.65)| (9.53) | (9.70) | (11.08)| (11.13)| (9.46) | (11.65)|        |
| **Pharmacy imputation** |        |        |        |        |        |        |        |        |        |
| Total available     | 1420   | 11,420 | 20,239 | 737    | 1124   | 6047   | 13     | 2861   | 43,861 |
| for analysis        |        |        |        |        |        |        |        |        |        |
| COSEHC score        | 31.94  | 31.95  | 30.93  | 31.07  | 36.13  | 31.18  | 36.85  | 36.60  | 31.77  |
| (9.08)              | (10.76)| (12.65)| (9.53) | (9.70) | (11.08)| (11.13)| (9.46) | (11.65)|        |
| **Multiple imputation** |        |        |        |        |        |        |        |        |        |
| Total available     | 1425   | 20,733 | 28,293 | 1127   | 2677   | 11,312 | 1963   | 3037   | 70,567 |
| for analysis        |        |        |        |        |        |        |        |        |        |
| COSEHC score        | 31.94  | 31.72  | 29.95  | 30.65  | 34.01  | 31.26  | 32.12  | 36.75  | 31.24  |
| (9.08)              | (10.85)| (11.57)| (9.47) | (11.01)| (11.42)| (10.94)| (10.45)| (11.24)|        |

Notes: All scores are presented as mean (standard deviation). aFor each site, total population includes all patients with ≥one visit in the eMR; bAccounts for laboratory and blood pressure values collected outside the original cutoff time of 12 months prior to inclusion; cAccounts for a missing history of diabetes from the eMR but the presence of diabetes-specific medications (insulin detemir, insulin glargine, human recombinant insulin, insulin lispro, metformin, pioglitazone, and rosiglitazone) in the pharmacy record; dAccounts for missing laboratory data from random visits using the Markov chain Monte Carlo method.

Abbreviations: COSEHC, Consortium for Southeastern Hypertension Control; eMR, electronic medical record.

Figure 1 COSEHC-17 versus COSEHC-11 risk score scatter plot with regression line and 95% confidence limits. The solid blue line shows the ordinary least-squares regression line (intercept = 3.19; slope = 1.05; R² = 0.93; P < 0.0001). The thin green lines represent the 95% confidence bounds. The outliers above the 95% confidence limits included primarily patients with a history of stroke or myocardial infarction. These two variables, while heavily weighted in the COSEHC-17 score, were typically unreported in the electronic medical record system and were relatively uncommon even in the complete dataset.

Abbreviation: COSEHC, Consortium for Southeastern Hypertension Control.
Translation of COSEHC scores into probability of cardiovascular death

The distribution of the COSEHC-11 score by decile for the 43,676-member cohort is shown in Table 4. The median (ie, 50th percentile) score is 34, with a range of 0 to 62. The distribution of the estimated COSEHC-17 scores, calculated using the regression coefficients found in the Figure, are also presented, as is the corresponding probability of cardiovascular death. Thus, for the median COSEHC-11 score of 34, which equates to an estimated COSEHC-17 score of 38.92, the cardiovascular death probability is 1.4%. A method for converting both the COSEHC-11 and COSEHC-17 risk scores to cardiovascular death probability is shown in Table 5. Because the data are presented in a tabular form rather than as a continuous function, several closely spaced COSEHC scores may be inferred to yield the same event probability.

Comparison of COSEHC, Framingham, PROCAM, and SCORE (Weibull) risk scores

Table 6 shows a comparison of the COSEHC, Framingham, PROCAM, and high- and low-risk SCORE (Weibull) risk scores calculated for men and women using both the complete and imputed GVRM data cohorts. Because the other three risk indices have different data requirements, the nonimputed sample sizes were smaller for Framingham (n = 23,683), PROCAM (n = 23,840), and SCORE (n = 23,787). For the imputed data cohort, the sample sizes also varied slightly across the Framingham, PROCAM, and COSEHC indices.

Table 4 Translation of COSEHC-11 score to COSEHC-17 score

| Percentile | COSEHC-11 score | COSEHC-17 score | Event probability |
|------------|----------------|----------------|------------------|
| 0          | 0              | 3.19           | 0.04%            |
| 10         | 14             | 17.91          | 0.19%            |
| 20         | 21             | 25.26          | 0.51%            |
| 30         | 27             | 31.57          | 0.84%            |
| 40         | 31             | 35.77          | 1.40%            |
| 50         | 34             | 38.92          | 1.40%            |
| 60         | 36             | 41.03          | 2.30%            |
| 70         | 40             | 45.23          | 3.70%            |
| 80         | 42             | 47.33          | 3.70%            |
| 90         | 44             | 49.43          | 3.70%            |
| 100        | 62             | 68.35          | 24.50%           |

Notes: Given there are 43,676 patients with all data necessary to calculate the COSEHC-11 risk score, there are approximately 4367 patients per decile (eg, 4367 patients between percentiles 0 and 10). *Calculated for the 43,676 patients with complete COSEHC-11 data; †Calculated using the results of the logistic regression model \( \text{COSEHC-17} = 3.19480 + 1.05084 \times \text{COSEHC-11} \); ‡Five-year risk of fatal coronary heart disease events.

Abbreviation: COSEHC, Consortium for Southeastern Hypertension Control.

Discussion

In this analysis of 177,404 patients enrolled in the COSEHC GVRM study, 43,676 patients had complete data for all 11 risk factors that comprise the COSEHC-11 cardiovascular risk score, and an additional 26,891 had at least eight of the 11 required variables. The mean COSEHC-11 risk score for the 43,676 patients who had available data for all 11 variables was 31.75. The inclusion of multiple imputations to
account for missing data points had a minimal impact on the mean COSEHC-11 risk score for the 70,567 patients who had at least eight of the 11 variables. In addition, linear regression analysis showed that the COSEHC-11 score was a significant predictor of the original, more comprehensive COSEHC-17 score. The high degree of correlation between the COSEHC-11 and 17 scores suggests that the simpler COSEHC-11 score is just as effective at predicting cardiovascular risk as the COSEHC-17 score, and can therefore be used to predict cardiovascular morbidity and mortality in patients whose electronic medical record may be lacking data for all 17 variables. Calculation of the Framingham, PROCAM, and high- and low-risk SCORE (Weibull) risk scores revealed that, for all but the PROCAM score, men have a higher predicted risk than women.

Aside from assessing achievement of COSEHC-recommended treatment goals and providing participating centers with benchmarking reports, one of the objectives of the GVRM study is to analyze the correlation between the COSEHC, Framingham, PROCAM, and SCORE (Weibull) coronary risk scores and the time to the first fatal or nonfatal coronary event over the five-year study duration to determine which score is most predictive for patients in the southeastern US. Although no single risk score is likely to be perfectly correlated with outcomes in all populations due to inherent variability, it is desirable to determine which score is most predictive for the majority of situations in a given population. Data suggest that the Framingham coronary risk score tends to overestimate risk,

### Table 5 Event probabilities associated with ranges of COSEHC-11 and COSEHC-17 scores

| COSEHC-11 lower bound | COSEHC-11 upper bound | Event probability | Range | COSEHC-17 lower bound | COSEHC-17 upper bound | Event probability | Range |
|-----------------------|----------------------|------------------|-------|-----------------------|----------------------|------------------|-------|
| 0.00 to 4.99          | 4.99                 | 0.04%            | 4.99  | -3.04 to 1.71         | 1.71                 | 0.04%            | 4.75  |
| 5.00 to 9.99          | 9.99                 | 0.07%            | 4.99  | 1.72 to 6.47          | 6.47                 | 0.07%            | 4.75  |
| 10.00 to 14.99        | 14.99                | 0.11%            | 4.99  | 6.48 to 11.22         | 11.22                | 0.11%            | 4.75  |
| 15.00 to 19.99        | 19.99                | 0.19%            | 4.99  | 11.23 to 15.98        | 15.98                | 0.19%            | 4.75  |
| 20.00 to 24.99        | 24.99                | 0.31%            | 4.99  | 15.99 to 20.74        | 20.74                | 0.31%            | 4.75  |
| 25.00 to 29.99        | 29.99                | 0.51%            | 4.99  | 20.75 to 25.50        | 25.50                | 0.51%            | 4.75  |
| 30.00 to 34.99        | 34.99                | 0.84%            | 4.99  | 25.51 to 30.26        | 30.26                | 0.84%            | 4.75  |
| 35.00 to 39.99        | 39.99                | 1.40%            | 4.99  | 30.27 to 35.01        | 35.01                | 1.40%            | 4.75  |
| 40.00 to 44.99        | 44.99                | 2.30%            | 4.99  | 35.02 to 39.77        | 39.77                | 2.30%            | 4.75  |
| 45.00 to 49.99        | 49.99                | 3.70%            | 4.99  | 39.78 to 44.53        | 44.53                | 3.70%            | 4.75  |
| 50.00 to 54.99        | 54.99                | 6.10%            | 4.99  | 44.54 to 49.29        | 49.29                | 6.10%            | 4.75  |
| 55.00 to 59.99        | 59.99                | 9.80%            | 4.99  | 49.30 to 54.05        | 54.05                | 9.80%            | 4.75  |
| 60.00 to 64.99        | 64.99                | 15.60%           | 4.99  | 54.06 to 58.81        | 58.81                | 15.60%           | 4.75  |
| 65.00 to 69.99        | 69.99                | 24.50%           | 4.99  | 58.82 to 63.56        | 63.56                | 24.50%           | 4.75  |
| 70.00 and up          | 63.57 and up         | 37.90%           |       | 37.90%                |                      |                  |       |

Notes: All scores are presented as mean (standard deviation). *Predicts 10-year risk of fatal or nonfatal CHD events; †Predicts 5-year risk of fatal CHD events; ‡Accounts for missing laboratory data from random visits using the Markov chain Monte Carlo method.

Abbreviations: CHD, coronary heart disease; COSEHC, Consortium for Southeastern Hypertension Control; PROCAM, Prospective Cardiovascular Münster; SCORE, Systemic Coronary Risk Evaluation.

### Table 6 Cardiovascular event probability calculated using the COSEHC-11, Framingham, PROCAM, and SCORE (Weibull) risk scores

|                  | Framingham* | PROCAM†  | SCORE‡ low-risk | SCORE‡ high-risk | COSEHC-11‡  |
|------------------|-------------|----------|-----------------|-----------------|-------------|
| **No imputation**|             |          |                 |                 |             |
| Men, n           | 11,006      | 11,163   | 11,136          | 11,136          | 16,951      |
| Probability      | 12.55 (7.74)| 20.07 (20.68)| 2.48 (2.62) | 4.96 (4.96)    | 3.15 (2.05) |
| Women, n         | 12,677      | 12,677   | 12,651          | 12,651          | 26,725      |
| Probability      | 5.90 (5.84)| 20.19 (22.22)| 1.63 (2.31) | 2.76 (3.76)    | 1.62 (1.81) |
| **Multiple imputation** |           |          |                 |                 |             |
| Men, n           | 31,825      | 32,329   | 32,082          | 32,082          | 32,329      |
| Probability      | 11.93 (7.79)| 19.75 (21.52)| 2.54 (2.86) | 5.07 (5.38)    | 2.68 (2.06) |
| Women, n         | 38,238      | 38,238   | 38,013          | 38,013          | 38,238      |
| Probability      | 5.47 (5.69)| 19.68 (22.64)| 1.62 (2.42) | 2.75 (3.93)    | 1.65 (1.81) |
particularly in nonwhite populations due to the derivation of the score from a primarily white cohort.\textsuperscript{12,13,16–19,29–31} Although the PROCAM and SCORE (Weibull) coronary risk scores were partly developed to address the limitations of the Framingham cardiovascular risk score, external validation data suggest that the PROCAM and SCORE (Weibull) risk scores also tend to overestimate coronary risk.\textsuperscript{18,19,31–33}

In the current era of rising health care costs and the increased pressure to provide adequate health care coverage for all persons, it is important to identify a patient’s true risk of coronary events correctly. For example, if a risk score systematically overestimates cardiovascular risk, then health care resources will be unnecessarily used and patients may be exposed to potentially unnecessary treatments.\textsuperscript{29} Conversely, if a risk score systematically underestimates cardiovascular risk, patients will be less likely to receive appropriate treatment, and resource utilization may increase due to the occurrence of more acute events. Thus, identification of a region-specific, accurate coronary risk score is desirable.

A unique aspect of the COSEHC GVRM study is the use of electronic medical records and the ease of data collection and validation. Using data from the patient’s actual medical record and not that recorded on a study-specific report form is more representative of the care patients receive in the “real world.” Another strength of the COSEHC GVRM study is that it includes only patients enrolled at COSEHC Centers of Excellence. Thus, it provides a unique tool for directly assessing the population living in the southeastern US, which has a different racial and ethnic composition compared with other areas of the US.

The COSEHC GVRM study does have several limitations. Although not proven, physicians at COSEHC Centers of Excellence may provide better care for their patients, and thus, the risk observed in the GVRM study cohort may underestimate the risk observed in the general population. This possibility is reflected in the high frequency of patients with controlled blood pressure (mean systolic blood pressure of $129 \pm 17$ mmHg) and lipid levels (mean plasma total cholesterol $4.8 \pm 1.1$ mmol/L [184 $\pm 42$ mg/dL], HDL-C $1.2 \pm 0.3$ mmol/L [47 $\pm 13$ mg/dL], and triglyceride levels $1.7 \pm 1.0$ mmol/L [151 $\pm 87$ mg/dL]) at study baseline. The ability to obtain certain patient demographics and clinical history variables from electronic medical records, including ethnicity, premature family CHD, history of LVH, smoking, and diabetes, can be difficult and is dependent on the electronic medical record system design, the effort of clinicians to report patient history, and, in some cases, the ability and willingness of patients to self-report history and demographic data. For example, family CHD history and LVH history are difficult to observe because they are not represented by an ICD-9 code and may only appear in a free-text comment area. Furthermore, the lack of a standardized definition of history of premature family CHD among providers, and it not being considered clinically important for older patients, suggests it may go unreported. In addition, while performance of echocardiography is typically reported in an electronic medical record, the objective test results defining LVH are not always included. Finally, as is true for any nonrandomized registry study, the influence of recruitment bias cannot be known.

In conclusion, these baseline data from the COSEHC GVRM study show there is excellent correlation between the original COSEHC-17 and the modified COSEHC-11 cardiovascular risk scores ($P < 0.0001; R^2 = 0.93$). Follow-up data collected over the next five years will demonstrate the predictive ability of the COSEHC cardiovascular risk score.
relative to the more widely used Framingham, PROCAM, and SCORE (Weibull) risk scores among patients in the southeastern US.

Acknowledgments
Partial support for this study was provided by grant 2PO1 HL-051952 from the National Heart, Lung and Blood Institute of the National Institutes of Health and Daichi Sankyo, Inc. We thank Melanie Leiby, PhD, of in Science Communications, a Wolters Kluwer business, for her editorial assistance in the preparation of this manuscript. We also thank Jeff Atwell of COSEHC for technical assistance and the following COSEHC Centers of Excellence investigators for participating in the DVRM: Bryan N Batson, Hattiesburg Clinic, Hattiesburg, MS; Michael Canfield, Palmetto Primary Care Physicians, North Charleston, SC; Alexander Cohen, Pee Dee Healthcare, Darlington, SC; Gary Goforth, Self Regional Healthcare, Greenwood, SC; Mark Houston, Hypertension Institute, St Thomas Hospital, Nashville, TN; and Steve Ross, Internal Medicine Specialists, Florence, SC.

Disclosure
The authors report no conflicts of interest in this work.

References
1. Daskalopoulou SS, Athyros VG, Kolovou GD, Anagnostopoulou KK, Mikhailidis DP. Definitions of metabolic syndrome: Where are we now? Curr Vasc Pharmacol. 2006;4(3):185–197.
2. National Cholesterol Education Program Adult Treatment Panel III. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106(25):3143–3421.
3. Andreassi MG. Metabolic syndrome, diabetes and atherosclerosis: Influence of gene-environment interaction. Mutat Res. 2009;667(1–2):35–43.
4. Kraja AT, Province MA, Arnett D, et al. Does inflammation and procoagulation relate to the metabolic syndrome cluster? Nutr Metab (Lond). 2007;4:28.
5. Potenza MV, Mechanick JJ. The metabolic syndrome: Definition, global impact, and pathophysiology. Nutr Clin Pract. 2009;24(5):560–577.
6. Gami AS, Witt BJ, Howard DE, et al. Metabolic syndrome and risk of incident cardiovascular events and death: A systematic review and meta-analysis of longitudinal studies. J Am Coll Cardiol. 2007;49(4):403–414.
7. de Simone G, Devereux RB, Chinali M, et al. Prognostic impact of metabolic syndrome by different definitions in a population with high prevalence of obesity and diabetes: The Strong Heart Study. Diabetes Care. 2007;30(7):1851–1856.
8. Dekker JM, Girman C, Rhodes T, et al. Metabolic syndrome and 10-year cardiovascular disease risk in the Hoorn Study. Circulation. 2005;112(5):666–673.
9. Ho JS, Cannaday JJ, Barlow CE, Mitchell TL, Cooper KH, Fitzgerald SJ. Relation of the number of metabolic syndrome risk factors with all-cause and cardiovascular mortality. Am J Cardiol. 2008;102(6):689–692.
10. Girman CJ, Dekker JM, Rhodes T, et al. An exploratory analysis of criteria for the metabolic syndrome and its prediction of long-term cardiovascular outcomes: The Hoorn study. Am J Epidemiol. 2005;162(5):438–447.
11. Redberg RF, Benjamin EJ, Bittner V, et al. ACCF/AHA 2009 performance measures for primary prevention of cardiovascular disease in adults: A report of the American College of Cardiology Foundation/American Heart Association task force on performance measures (writing committee to develop performance measures for primary prevention of cardiovascular disease): developed in collaboration with the American Academy of Family Physicians; American Association of Cardiovascular and Pulmonary Rehabilitation; and Preventive Cardiovascular Nurses Association: endorsed by the American College of Preventive Medicine, American College of Sports Medicine, and Society for Women’s Health Research. Circulation. 2009;120(13):1296–1336.
12. D’Agostino RB Sr, Grundy S, Sullivan LM, Wilson P. Validation of the Framingham coronary heart disease prediction scores: Results of a multiple ethnic groups investigation. JAMA. 2001;286(2):180–187.
13. Hemmang BA, Bimson WF, Taylor AJ. The Framingham Risk Score: An appraisal of its benefits and limitations. Am Heart Hosp J. 2007;5(2):91–96.
14. Mancia G, de Backer G, Dominiczak A, et al. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2007;28(12):1462–1536.
15. Sehestedt T, Jeppesen J, Hansen TW, et al. Risk prediction is improved by adding markers of subclinical organ damage to SCORE. Eur J Clin Invest. 2010;40(7):883–891.
16. Schlendorf KH, Nasir K, Blumenthal RS. Limitations of the Framingham risk score are now much clearer. Prev Med. 2009;48(2):115–116.
17. Liu J, Hong Y, D’Agostino RB Sr, et al. Predictive value for the Chinese population of the Framingham CHD risk assessment tool compared with the Chinese Multi-Provincial Cohort Study. JAMA. 2004;291(21):2591–2599.
18. van der Heijden AA, Ortegon MM, Niessen LW, Niijpels G, Dekker JM. Prediction of coronary heart disease risk in a general, pre-diabetic, and diabetic population during 10 years of follow-up: Accuracy of the Framingham, SCORE, and UKPDS risk functions: The Hoorn Study. Diabetes Care. 2009;32(11):2094–2098.
19. Empama JP, Ducimetière P, Arveiler D, et al. Are the Framingham and PROCAM coronary heart disease risk functions applicable to different European populations? The PRIME Study. Eur J Heart J. 2003;24(21):1903–19111.
20. Assmann G, Cullen P, Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the Prospective Cardiovascular Munster (PROCAM) study. Circulation. 2002;105(3):310–315.
21. Conroy RM, Pyörälä K, Fitzgerald AP, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: The SCORE project. Eur Heart J. 2003;24(11):987–1003.
22. Hall WD, Ferrario CM, Moore MA, et al. Hypertension-related morbidity and mortality in the southeastern United States. Am J Med Sci. 1997;313(4):195–209.
23. Lloyd-Jones D, Adams RJ, Brown TM, et al. Heart disease and stroke statistics – 2010 Update. A report from the American Heart Association. Circulation. 2010;121(7):e46–e215.
24. Pocock SJ, McCormack V, Gueyffier F, Boutitie F, Fagard RH, Boissel JP. A score for predicting risk of death from cardiovascular disease in adults with raised blood pressure, based on individual patient data from randomised controlled trials. BMJ. 2001;323(7304):75–81.
25. Houston MC, Basile J, Bestermann WH, et al. Addressing the global cardiovascular risk of hypertension, dyslipidemia, and insulin resistance in the southeastern United States. Am J Med Sci. 2005;329(6):276–291.
26. Bestermann W, Houston MC, Basile J, et al. Addressing the global cardiovascular risk of hypertension, dyslipidemia, diabetes mellitus, and the metabolic syndrome in the southeastern United States, part II: Treatment recommendations for management of the global cardiovascular risk of hypertension, dyslipidemia, diabetes mellitus, and the metabolic syndrome. *Am J Med Sci*. 2005;329(6):292–305.

27. SAS Institute, Inc. The MI procedure. *SAS OnlineDoc® 9.1.3*. Cary, NC: SAS Institute; 2008.

28. Kass RE, Carlin BP, Gelman A, Neal RM. Markov chain Monte Carlo in practice: A roundtable discussion. *Am Stat*. 1998;52:93–100.

29. Collins GS, Altman DG. An independent external validation and evaluation of QRISK cardiovascular risk prediction: A prospective open cohort study. *BMJ*. 2009;339:b2584.

30. Brindle P, Emberson J, Lampe F, et al. Predictive accuracy of the Framingham coronary risk score in British men: Prospective cohort study. *BMJ*. 2003;327(7426):1267.

31. Cooper JA, Miller GJ, Humphries SE. A comparison of the PROCAM and Framingham point-scoring systems for estimation of individual risk of coronary heart disease in the Second Northwick Park Heart Study. *Atherosclerosis*. 2005;181(1):93–100.

32. Neuhauser HK, Ellert U, Kurth BM. A comparison of Framingham and SCORE-based cardiovascular risk estimates in participants of the German National Health Interview and Examination Survey 1998. *Eur J Cardiovasc Prev Rehabil*. 2005;12(5):442–450.

33. Ulmer H, Kollerits B, Kelleher C, Diem G, Concin H. Predictive accuracy of the SCORE risk function for cardiovascular disease in clinical practice: A prospective evaluation of 44,649 Austrian men and women. *Eur J Cardiovasc Prev Rehabil*. 2005;12(5):433–441.